In this trial, we are evaluating the safety, and tolerability of a new medication for the potential treatment of degenerative and inflammatory diseases. This medication is a Receptor–Interacting Protein 1 (RIP1) inhibitor. Receptor interacting protein 1 acts as a mediator in cell death processes, which causes inflammatory responses. This medication may inhibit this process and is therefore being developed as a potential treatment.
For this trial we need the help of male and female participants who are not pregnant or breastfeeding, aged from 18 to 45 (inclusive) who are in good health, are non-smokers or only smoke no more than 2 cigarettes per day, and do not have a history of any medical conditions.
This study is currently not recruiting further participants.